Acamprosate efficacy in alcohol-dependent patients: Summary of results from three pivotal trials

American Journal on Addictions

Volumn 17, Issue 1, 2008, Pages 70-76

  Kranzler, Henry R ^a   Gage, Allyson ^b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; PLACEBO;

ALCOHOL ABSTINENCE; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; DATA ANALYSIS; DRINKING BEHAVIOR; DRUG EFFICACY; HUMAN;

ADULT; ALCOHOL DETERRENTS; ALCOHOLISM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAURINE; TREATMENT OUTCOME;

EID: 38549168312     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1080/10550490701756120     Document Type: Article

References (35)

1. Grant BF, Dawson DA, Stinson FS, Chou SP, Dufour MC, Pickering RP. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend. 2004;74:223-234.
2. Chase V, Neild R, Sadler CW, Batey RG. The medical complications of alcohol use: understanding mechanisms to improve management. Drug Alcohol Rev. 2005;24:253-265.
3. Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of alcohol dependence: A review of the evidence. JAMA. 1999;281:1318-1325.
4. Harwood H. Updating Estimates of the Economic Costs of Alcohol Abuse in the United States: Estimates, Update Methods, and Data. Report prepared by The Lewin Group for the National Institute on Alcohol Abuse and Alcoholism. Rockville, Md.: US Department of Health and Human Services; 2000.
5. Cohen E, Feinn R, Arias A, Kranzler HR. Alcohol treatment utilization: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend. 2007; 86:214-221.
6. Mark TL, Kranzler HR, Song X. Understanding U.S. addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend. 2003;71:219-228.
7. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-3105.
8. Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. National trends in the outpatient treatment of depression. JAMA. 2002;287:203-209.
9. Friedmann PD, McCullough D, Chin MH, Saitz R. Screening and intervention for alcohol problems. A national survey of primary care physicians and psychiatrists. J Gen Intern Med. 2000;15:84-91.
10. Mark TL, Kranzler HR, Song X, Bransberger P, Poole VH, Crosse S. Physicians' opinions about medications to treat alcoholism. Addiction. 2003;98:617-626.
11. Anton RF, Swift RM. Current pharmacotherapies of alcoholism: A U.S. perspective. Am J Addict. 2003;12 (Suppl. 1):S53-S68.
12. Finney JW, Hahn AC, Moos RH. The effectiveness of inpatient and outpatient treatment for alcohol abuse: The need to focus on mediators and moderators of setting effects. Addiction. 1996;91:1773-1796.
13. Friedmann PD, Saitz R, Samet JH. Management of adults recovering from alcohol or other drug problems: Relapse prevention in primary care. JAMA. 1998;279:1227-1231.
14. O'Brien CP, McLellan AT. Addiction medicine. JAMA. 1997;277:1840-1841.
15. Swift RM. Drug therapy for alcohol dependence. N Engl J Med. 1999;340:1482-1490.
16. De Witte P. Imbalance between neuroexcitatory and neuroinhibitory amino acids causes craving for ethanol. Addict Behav. 2004;29:1325-1339.
17. Kumari M, Ticku MK. Regulation of NMDA receptors by ethanol. Prog Drug Res. 2000;54:152-189.
18. Littleton J. Acamprosate in alcohol dependence: How does it work? Addiction. 1995;90:1179-1188.
19. DeWitte P, Littleton J, Parot P, Koob G. Neuroprotective and abstinence-promoting effects of acamprosate: Elucidating the mechanism of action. CNS Drugs. 2005;19:517-537.
20. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: Results of a meta-analysis. Alcohol Clin Exp Res. 2004;28:51-63.
21. Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: The role of patient motivation. J Psychiatr Res. 2006;40:383-393.
22. Bouza C, Magro A, Munoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction. 2004;99:811-828.
23. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study - a randomized controlled trial. JAMA. 2006;295:2003-2017.
24. Morley KC, Teesson M, Reid SC, et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. Addiction. 2006;101:1451-1462.
25. Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry. 1997;171:73-77.
26. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry. 1996;53:673-680.
27. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995;30:239-247.
28. rd ed., revised. Washington, DC: American Psychiatric Association; 1987.
29. Rosenberg H, Davis LA. Acceptance of moderate drinking by alcohol treatment services in the United States. J Stud Alcohol. 1994;55:167-172.
30. Namkoong K, Lee BO, Lee PG, Choi MJ, Lee E. Acamprosate in Korean alcohol-dependent patients: A multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol. 2003;38:135-141.
31. Chick J, Howlett H, Morgan MY, Ritson B. United Kingdom Multicentre Acamprosate Study (UKMAS): A six-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol. 2000;35:176-187.
32. Mason BJ. Acamprosate for alcohol dependence: An update for the clinician. Focus. 2006;IV:505-511.
33. Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA. 2000;284:963-971.
34. Kranzler HR, Burleson JA, Brown J, Babor TF. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res. 1996;20:1534-1541.
35. Johnson BA. An overview of the development of medications including novel anticonvulsants for the treatment of alcohol dependence. Expert Opin Pharmacother. 2004;5:1943-1955.